Question 1

Purpose of Evaluation

Accepted Answer

Early detection of Human Platelet Antigen (HPA) incompatibility. Preventing intracranial hemorrhage (ICH) in the fetus or newborn. Determining the need for Intravenous Immunoglobulin (IVIG) therapy during pregnancy.

Question 2

Target Groups

Accepted Answer

Mothers with a history of a previous child affected by neonatal thrombocytopenia. Pregnant women with identified platelet antibodies. Families with a genetic history of fetal bleeding disorders.

Question 3

Management Protocol

Accepted Answer

Regular maternal blood tests to monitor antibody levels. Advanced ultrasound imaging to monitor fetal growth and signs of hemorrhage. Coordinated delivery planning to ensure appropriate platelet availability if needed.

Protect Your Baby from FNAIT - Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Evaluation